Neurovalens raises over £5m as it seeks regulatory approval
July 20, 2020
Irish healthtech company Neurovalens has raised £5.1 million (€5.6 million) as it looks to secure regulatory approval for headset it has developed that can be used to help treat a range of conditions, including insomnia.
The company, which is dual-headquartered in Belfast and San Diego, is to use the new financing to expand on the success of initial clinical trials and further develop its technology for use with other medical conditions.
The latest fundraise brings total investment in the company to date to over £11 million It was led by long-term backer IQ Capital. Other participants included Wharton Asset Management Company, The Angel CoFund, Techstart Ventures, Co-Fund II managed by Clarendon Fund Managers and the UK government’s Future Fund.
Read the full story on the Irish Times website here